Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1β activity
MK Roell, H Issafras, RJ Bauer, KS Michelson… - Journal of biological …, 2010 - ASBMB
Many therapeutic antibodies act as antagonists to competitively block cellular signaling
pathways. We describe here an approach for the therapeutic use of monoclonal antibodies
based on context-dependent attenuation to reduce pathologically high activity while
allowing homeostatic signaling in biologically important pathways. Such attenuation is
achieved by modulating the kinetics of a ligand binding to its various receptors and
regulatory proteins rather than by complete blockade of signaling pathways. The anti …
pathways. We describe here an approach for the therapeutic use of monoclonal antibodies
based on context-dependent attenuation to reduce pathologically high activity while
allowing homeostatic signaling in biologically important pathways. Such attenuation is
achieved by modulating the kinetics of a ligand binding to its various receptors and
regulatory proteins rather than by complete blockade of signaling pathways. The anti …
